Eve Shinbrot
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Recognitions
Eve Shinbrot has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
Stacey B. Gabriel
47 shared publicationsChris Sander
35 shared publicationsLiu Xi
35 shared publicationsDavid A. Wheeler
34 shared publicationsRichard A. Gibbs
34 shared publicationsJaegil Kim
33 shared publications
Latest Publications
- Open Access
- 16 April 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (11)
NOTCH1 acts as a tumor suppressor that induces early differentiation in head and neck cancer
Inactivating NOTCH1 mutations in head and neck squamous cell carcinoma (HNSCC) were described over a decade ago, suggesting a tumor suppressor function — unlike its oncogenic role in other tumors. Today, much debate persists regarding a putative oncogenic role in HNSCC as well, with reports that NOTCH1 signaling drives tumor growth and a cancer stem cell (CSC) phenotype. In this work, comprehensive experiments unequivocally demonstrate that NOTCH1 is a tumor suppressor in HNSCC regardless of mutation or activation status and that it reduces CSC frequency. We developed a signature of NOTCH1 activation showing the pathway is associated with very early differentiation, an altered tumor microenvironment, and better prognosis. Clarifying whether NOTCH1 occasionally functions as an oncogenic driver in HNSCC is crucial to prognosis and personalized therapy. The results presented unify the field, reconcile conflicting data, and provide critical insights into the biological and clinical significance of NOTCH1 , with broader implications in other squamous carcinomas with NOTCH1 mutations.
- 16 April 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (11)
Open AccessNOTCH1 acts as a tumor suppressor that induces early differentiation in head and neck cancer
Inactivating NOTCH1 mutations in head and neck squamous cell carcinoma (HNSCC) were described over a decade ago, suggesting a tumor suppressor function — unlike its oncogenic role in other tumors. Today, much debate persists regarding a putative oncogenic role in HNSCC as well, with reports that NOTCH1 signaling drives tumor growth and a cancer stem cell (CSC) phenotype. In this work, comprehensive experiments unequivocally demonstrate that NOTCH1 is a tumor suppressor in HNSCC regardless of mutation or activation status and that it reduces CSC frequency. We developed a signature of NOTCH1 activation showing the pathway is associated with very early differentiation, an altered tumor microenvironment, and better prognosis. Clarifying whether NOTCH1 occasionally functions as an oncogenic driver in HNSCC is crucial to prognosis and personalized therapy. The results presented unify the field, reconcile conflicting data, and provide critical insights into the biological and clinical significance of NOTCH1 , with broader implications in other squamous carcinomas with NOTCH1 mutations.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supp. Tables S1, S3-S15, S20, and S23 from Genetic Mechanisms of Immune Evasion in Colorectal Cancer
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupp. Tables S1, S3-S15, S20, and S23 from Genetic Mechanisms of Immune Evasion in Colorectal Cancer
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supp. Table S22 from Genetic Mechanisms of Immune Evasion in Colorectal Cancer
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupp. Table S22 from Genetic Mechanisms of Immune Evasion in Colorectal Cancer
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supp. Table S2 from Genetic Mechanisms of Immune Evasion in Colorectal Cancer
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupp. Table S2 from Genetic Mechanisms of Immune Evasion in Colorectal Cancer
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supp. Tables S16-S19 from Genetic Mechanisms of Immune Evasion in Colorectal Cancer
Supplementary Tables S16-S19, describing IHC results on NHS/HPFS data
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupp. Tables S16-S19 from Genetic Mechanisms of Immune Evasion in Colorectal Cancer
Supplementary Tables S16-S19, describing IHC results on NHS/HPFS data
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Genetic Mechanisms of Immune Evasion in Colorectal Cancer
To understand the genetic drivers of immune recognition and evasion in colorectal cancer, we analyzed 1,211 colorectal cancer primary tumor samples, including 179 classified as microsatellite instability–high (MSI-high). This set includes The Cancer Genome Atlas colorectal cancer cohort of 592 samples, completed and analyzed here. MSI-high, a hypermutated, immunogenic subtype of colorectal cancer, had a high rate of significantly mutated genes in important immune-modulating pathways and in the antigen presentation machinery, including biallelic losses of B2M and HLA genes due to copy-number alterations and copy-neutral loss of heterozygosity. WNT/β-catenin signaling genes were significantly mutated in all colorectal cancer subtypes, and activated WNT/β-catenin signaling was correlated with the absence of T-cell infiltration. This large-scale genomic analysis of colorectal cancer demonstrates that MSI-high cases frequently undergo an immunoediting process that provides them with genetic events allowing immune escape despite high mutational load and frequent lymphocytic infiltration and, furthermore, that colorectal cancer tumors have genetic and methylation events associated with activated WNT signaling and T-cell exclusion.Significance: This multi-omic analysis of 1,211 colorectal cancer primary tumors reveals that it should be possible to better monitor resistance in the 15% of cases that respond to immune blockade therapy and also to use WNT signaling inhibitors to reverse immune exclusion in the 85% of cases that currently do not. Cancer Discov; 8(6); 730–49. ©2018 AACR.This article is highlighted in the In This Issue feature, p. 663
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Genetic Mechanisms of Immune Evasion in Colorectal Cancer
To understand the genetic drivers of immune recognition and evasion in colorectal cancer, we analyzed 1,211 colorectal cancer primary tumor samples, including 179 classified as microsatellite instability–high (MSI-high). This set includes The Cancer Genome Atlas colorectal cancer cohort of 592 samples, completed and analyzed here. MSI-high, a hypermutated, immunogenic subtype of colorectal cancer, had a high rate of significantly mutated genes in important immune-modulating pathways and in the antigen presentation machinery, including biallelic losses of B2M and HLA genes due to copy-number alterations and copy-neutral loss of heterozygosity. WNT/β-catenin signaling genes were significantly mutated in all colorectal cancer subtypes, and activated WNT/β-catenin signaling was correlated with the absence of T-cell infiltration. This large-scale genomic analysis of colorectal cancer demonstrates that MSI-high cases frequently undergo an immunoediting process that provides them with genetic events allowing immune escape despite high mutational load and frequent lymphocytic infiltration and, furthermore, that colorectal cancer tumors have genetic and methylation events associated with activated WNT signaling and T-cell exclusion.Significance: This multi-omic analysis of 1,211 colorectal cancer primary tumors reveals that it should be possible to better monitor resistance in the 15% of cases that respond to immune blockade therapy and also to use WNT signaling inhibitors to reverse immune exclusion in the 85% of cases that currently do not. Cancer Discov; 8(6); 730–49. ©2018 AACR.This article is highlighted in the In This Issue feature, p. 663
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supp. Table S21 from Genetic Mechanisms of Immune Evasion in Colorectal Cancer
Supplementary Table S21: Segmented copy-number ratios
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupp. Table S21 from Genetic Mechanisms of Immune Evasion in Colorectal Cancer
Supplementary Table S21: Segmented copy-number ratios
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supp. Table S21 from Genetic Mechanisms of Immune Evasion in Colorectal Cancer
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupp. Table S21 from Genetic Mechanisms of Immune Evasion in Colorectal Cancer
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supp. Figures and Legends from Genetic Mechanisms of Immune Evasion in Colorectal Cancer
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupp. Figures and Legends from Genetic Mechanisms of Immune Evasion in Colorectal Cancer
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supp. Figures and Legends from Genetic Mechanisms of Immune Evasion in Colorectal Cancer
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupp. Figures and Legends from Genetic Mechanisms of Immune Evasion in Colorectal Cancer